Shang Hai Zheng Quan Bao·2026-02-24 17:10Group 1 - The company received a supplementary application approval notice from the National Medical Products Administration for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier), expanding the age range for its use from "3 months to 3 years (47 months) children" to "3 months to 6 years (83 months) children" [1][3] - The product, branded as "Mankai Xin," is the first quadrivalent meningococcal conjugate vaccine approved in China, which was launched in December 2021, addressing the gap in high-end vaccines in the country and providing a better solution for preventing meningococcal disease in children under 6 years old [2] - The expansion of the age range for the vaccine is expected to positively impact the company's performance and facilitate further promotion and use of the vaccine, with the company committed to advancing production, batch release, and market sales [3]